144 тысяч подписчиков
14 тысяч видео
Acquired von Willebrand disease in Waldenström’s macroglobulinemia: diagnosis and treatment
Adverse events associated with BTKis in the treatment of Waldenström’s macroglobulinemia
WM-NET: upcoming clinical trials to advance the treatment of WM
Multi-omic analysis in WM: progress being made and challenges that remain
A Phase II study investigating epcoritamab in the treatment of Waldenström’s macroglobulinemia
The evolving role of genomics in the treatment of WM: MYD88, CXCR4, and TP53
The potential of fixed-duration BTKis and using MRD to guide treatment discontinuation in WM
Multi-omics studies to understand the progression from premalignant states to WM
Hyperviscosity syndrome as a complication in WM and its management with plasma exchange
Ibrutinib plus rituximab in symptomatic Japanese patients with Waldenström's macroglobulinemia
The diverse presentation of symptoms in patients with Waldenström's macroglobulinemia
The role of the microenvironment and stromal components in WM progression and drug resistance
Single-cell sequencing of circulating tumor cells to predict progression from MGUS/SMM
Lymphoma highlights from ASH 2021
The value of using next-generation flow cytometry to measure MRD status
The multi-cohort SCHOLAR-1 study of refractory aggressive DLBCL
The complications of treating elderly patients with AML
Key myeloma discussion topics at LLM 2021
The application of AI in healthcare and in clinical practice
Atezolizumab-obinutuzumab-venetoclax in follicular lymphoma and MZL
CITADEL-204: parsaclisib in R/R MZL
What impact do side effects have on elderly chronic myeloid leukemia (CML) patients?
Single-cell transcriptomic analysis of B-ALL: leukemia cell state and genetic alterations
Emerging treatment options for MZL
CITADEL-204: safety and efficacy of parsaclisib in R/R MZL
ALL and CLL updates at ASCO 2021
The challenges of treating older patients with Hodgkin lymphoma
Phase 1 trials of novel CAR T-cells for leukemia
Cellular and targeted therapies for Hodgkin lymphoma
MAGNOLIA trial: zanubrutinib for MZL
The evolution of treatment for elderly patients with CLL
RELEVANCE: Rituximab and lenalidomide in FL
The changing landscape of BTK inhibitor therapy in patients with MZL
Current status of third-line therapy for CML
The role of NK cells in preventing relapse in leukemia
CAR-T therapy, a novel promising treatment option for chronic hepatitis B and HBV-associated HCC
Updates on cellular and molecular interactions in the CLL microenvironment
Shifting the treatment landscape of ITP: novel agents and future outlooks
Pembrolizumab trial shows promising responses in cutaneous lymphoma
Impact of cytogenetic abnormalities on OS following SCT in pediatric AML
The impact of age on the prognosis of patients with ALL
Longitudinal UBA1 tracking in VEXAS syndrome
Choosing the best BTK inhibitor for managing CLL
Late effect surveillance following alloSCT: the publication of new guidelines
MRD negativity assessed by flow cytometry associated with improved outcomes in NPM1-mutated AML
New targets to treat acute myeloid leukemia (AML) with FLT3 mutations
EHA and ASCO 2023 highlights: promising treatments in AML, MDS, and ALL
PTCy versus ATG as haploidentical transplant prophylaxis
Collaboration without borders: the international relationships of EHA
Zanubrutinib plus obinutuzumab: CLL, SLL & FL
AlloCARs and CAR-NK cells in myeloma
Efficacy & tolerability of anti-thrombotic therapy in patients with HHT
Bispecific CAR T-cell therapy: combining anti-CD19 and CD22 CAR T-cells
MPN highlights from EHA 2016
Novel therapies and ongoing trials in NHL: advances in antibody-based combinations
Phase I study of CD5 CAR-T therapy manufactured with TKIs in R/R T-ALL
Precision-T trial: Orca-T vs tacrolimus-methotrexate for GvHD prevention in hematologic malignancies
Practice-changing updates in CLL from ASH 2024: findings from the AMPLIFY trial
Insights into the mechanisms leading to progression from MGUS and SMM to multiple myeloma
Insights into the BrECADD regimen in HL & results from the GHSG HD21 study
Using genomic alterations to predict relapse following immunotherapy in multiple myeloma
The future of leukemia treatment leans towards immunotherapy
